8-K: 60 Degrees Pharma Details Growth Strategy, Babesiosis Trials

60 Degrees Pharmaceuticals outlines its strategy for increasing ARAKODA sales, focusing on chronic babesiosis and malaria prevention, alongside ongoing clinical trials and regulatory goals.

Summary

• The company's Chief Executive Officer, Geoff Dow, is scheduled to provide investor information, including a detailed investor presentation.
• Current market capitalization stands at $5.8 million as of September 2025.
• ARAKODA sales for chronic babesiosis are increasing, with US Pharmacy Deliveries reaching 1,082 units in Q2 2025, down from 1,579 in Q1 2025 due to a temporary stock-out.
• Net Revenue for Q2 2025 was $51,000, with a gross margin of 50%, compared to $90,000 net revenue and 55% gross margin in Q1 2025.
• The company projects future ARAKODA sales for chronic babesiosis could increase by orders of magnitude, potentially exceeding malaria prevention sales, assuming FDA approval.
• Three clinical trials for ARAKODA are underway to confirm efficacy against babesiosis, with earliest completion dates ranging from October 15, 2025, to December 31, 2025.
• The earliest feasible New Drug Application (NDA) submission date for babesiosis is Q4 2026.
• Key milestones for 2025-2026 include market research outputs for babesiosis, sales outputs from the ARAKODA commercial pilot, first data outputs from babesiosis trials, and decisions on FDA regulatory goals.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive, reflecting significant potential in the babesiosis market and ongoing clinical trials, balanced by current financial challenges, small market cap, and explicit going-concern risk.

Positives

• ARAKODA sales for chronic babesiosis are increasing, indicating a growing market for this indication.
• Gross margins are strong, with Q2 2025 at 50% and Q1 2025 at 55%, suggesting good product profitability.
• Internal market research suggests future ARAKODA sales for chronic babesiosis could be significantly higher than for malaria prevention, representing a substantial growth opportunity.
• ARAKODA offers a lower pill burden for malaria prophylaxis (16 pills for a one-month trip) compared to standard care (53 pills), which is a competitive advantage.
• Tafenoquine, the active ingredient in ARAKODA, demonstrated an 80% cure rate in 5 immunosuppressed babesiosis patients in a study, showing promising efficacy.
• Achieved 140% year-over-year revenue growth in Q1 2025.

Negatives

• The company's market capitalization is relatively small at $5.8 million, indicating a micro-cap status.
• Q2 2025 US Pharmacy Deliveries and Net Revenue were down compared to Q1 2025 due to a temporary stock-out, impacting short-term performance.
• Brand recognition for ARAKODA is low, requiring significant marketing efforts.
• Generic alternatives for malaria prevention have lower out-of-pocket costs, posing a competitive challenge.
• The G6PD testing requirement for ARAKODA is a potential barrier for some travelers.

Risks

• There is substantial doubt as to the company's ability to continue on a going-concern basis.
• The company might not be eligible for Australian government research and development tax rebates.
• Inability to successfully develop, obtain FDA approval for, and commercialize non-malaria prevention indications for Tafenoquine (ARAKODA or other regimen) or Celgosivir/Australian Chestbut extracts in a timely manner could hinder business expansion.
• The company cannot guarantee its ability to conduct successful clinical trials.
• Lack of manufacturing capacity poses the risk of lengthy and costly delays in bringing products to market.

Future Outlook

The company's future outlook is focused on achieving FDA approval for ARAKODA in babesiosis, with an earliest feasible NDA submission target of Q4 2026. This involves completing three ongoing clinical trials by late 2025, gathering market research and epidemiologic data, and executing a commercial pilot for malaria to address market barriers. The company anticipates significant sales growth for ARAKODA, particularly in chronic babesiosis, which could exceed malaria prevention sales, assuming regulatory success.

Management Comments

• Geoffrey Dow, Chief Executive Officer and President, is scheduled to provide investor information.
• Roberts wrote, 'Malaria is an awful disease that needs to be attacked full-force when a diagnosis is made. In my time here, I’ve gone from being so sick that any dog would take pity on me to being ready to fire up the grill on Labor Day (well, maybe ready to watch the grill being fired up).'
• Dr. Richard Horowitz stated, 'Chronic Babesiosis is seen in the vast majority of my chronically ill patients with Lyme disease. Present regimens with Mepron and Zithromax or clindamycin and quinine are insufficient in many cases to clear the infection. We need more studies on drugs like tafenoquine, for Chronic Babesiosis, as this persistent parasite is one of the reasons my patients do not get better.'
• Dr. Shannon Delaney commented, 'Every week I see kids and adults who have manifestations of Chronic Babesiosis, often presenting as severe neuropsychiatric symptoms.'

Industry Context

The company operates in the infectious disease pharmaceutical sector, addressing the growing problem of malaria in travelers due to medication non-compliance and the emerging challenge of babesiosis, a tick and blood-borne parasitic infection. The presentation highlights the complexity of selecting antimalarial prophylaxis and the limitations of conventional babesiosis treatments in fully eradicating the parasite, positioning ARAKODA as a potential solution for both. The focus on chronic babesiosis aligns with a recognized unmet medical need among physicians treating chronically ill patients.

Comparison to Industry Standards

• ARAKODA offers a significantly lower pill burden for malaria prophylaxis (16 pills for a one-month trip) compared to the standard of care Atovaquone/proguanil/primaquine (53 pills).
• Conventional treatments for babesiosis, such as Mepron and Zithromax or clindamycin and quinine, are noted by physicians like Dr. Richard Horowitz as often insufficient to clear persistent infections, highlighting a gap ARAKODA aims to fill.
• The company's market research indicates that future ARAKODA sales for chronic babesiosis could be higher than for malaria, suggesting a potentially larger market opportunity than its current primary indication.

Stakeholder Impact

• Shareholders face potential for significant upside if clinical trials and FDA approvals are successful, but also substantial risk due to the company's going-concern status and early stage of development for new indications.
• Patients suffering from chronic babesiosis and those needing malaria prophylaxis could benefit from a new, effective treatment option with a lower pill burden.
• Healthcare providers may gain an additional tool for treating babesiosis and preventing malaria, especially if ARAKODA's advantages are clearly differentiated.
• Creditors may face increased risk given the 'going-concern' doubt.

Next Steps

• Complete initial enrollment for Babesiosis Trial #1 (NCT06207370) by October 15, 2025.
• Start Babesiosis Trial #3 (NCT06656351) by October 31, 2025.
• Complete Babesiosis Trial #2 (NCT06478641) and Trial #3 (NCT06656351) by December 31, 2025.
• Obtain market research and epidemiologic outputs for babesiosis in Q3/Q4 2025.
• Generate sales outputs from the ARAKODA Commercial Pilot by Q4 2025 (earliest).
• Receive first data outputs from babesiosis trials by Q4 2025 (earliest).
• Make decisions on FDA regulatory goals in the near term.
• Submit New Drug Application (NDA) for babesiosis no earlier than Q4 2026.
• Pursue new product development collaborations.
• Provide market updates and attend trade & scientific conferences.

Key Dates

Recommendation

The company presents a compelling long-term growth story centered on the significant, underserved market for chronic babesiosis, where ARAKODA shows promising early data. The potential for sales to increase by 'orders of magnitude' is attractive. However, the 'substantial doubt as to our ability to continue on a going-concern basis,' the early stage of clinical trials for the babesiosis indication, the lack of manufacturing capacity, and the competitive landscape for malaria prevention introduce considerable risk. While the upside is notable, the current financial fragility and regulatory hurdles warrant a cautious 'hold' recommendation for seasoned investors, awaiting clearer progress on clinical trials, FDA approvals, and improved financial stability before considering a stronger position.

Keywords

Pharmaceuticals, Babesiosis, Malaria, Tafenoquine, ARAKODA, Clinical Trials, FDA Approval, Drug Development, Infectious Disease, Biotechnology, SEC Filing, Investor Presentation